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ABSTRACT: The D-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptors are a family of glutamate 
ion channels of considerable interest in excitatory neurotransmission and associated disease processes. Here, we 
demonstrate how exploitation of the available X-ray crystal structure of the receptor ligand binding domain enabled the 
development of a new class of AMPA receptor positive allosteric modulators (7) through hybridization of known ligands 
(5 and 6), leading to a novel chemotype with promising pharmacological properties. 
The D-amino-3-hydroxy-5-methyl-4-isoxazole-propionic 
acid (AMPA) receptors are a class of ligand gated ion 
channels that are ubiquitously expressed in the central 
nervous system (CNS). This sub-family of glutamate 
receptors is considered to be responsible for the vast 
majority of fast excitatory amino acid neurotransmission 
in the CNS.1 A postulated function of AMPA receptors is 
in facilitating the process of synaptic plasticity and long-
term potentiation (LTP), a use dependent potentiation of 
synaptic efficacy often considered to be responsible for 
encoding both learning and memory. Various classes of 
AMPA receptor modulators have demonstrated their 
potential in enhancing LTP; and accordingly are being 
considered as potential new treatments for a raft of dis-
eases in the neurosciences area, including $O]KHLPHU¶V
Disease, schizophrenia, ParkinVRQ¶VGLVHDVHDQG$WWHn-
tion Deficit Hyperactivity Disorder.2,3 
Four distinct genes (GluA1 to 4) encode subunits of the 
AMPA receptor, each consisting of four discernable do-
mains: an N-terminal region, an extracellular glutamate 
binding site (ligand binding domain, LBD), a 
transmembrane region and a C-terminal domain.4 Con-
siderable advances have been made in solving the 
three-dimensional structure of the AMPA receptor. X-ray 
structures have been reported of protein complexes rep-
resenting the LBD5 and more latterly the full-length re-
ceptor.6 
Based on the strong association with neurological dis-
orders, significant effort has been invested in the identifi-
cation of AMPA receptor positive modulators as cogni-
tion enhancers.7 Pre-eminent among this class of small 
molecules are benzamide derivatives such as 
aniracetam (1),8 the progenitor compound in this series; 
CX516 (2)9 and CX614 (3),10 Chart 1.  
 
 
Chart 1. Benzamide derived AMPA receptor modula-
tors 
Although compounds such as 2 display promising ac-
tivity in behavioral paradigms related to cognition,11 rela-
tively high doses (35 mg/kg) are required, attributable in 
part to the low in vitro potency of the compounds (e.g. 
EC50 = 150 PM in native tissue preparations for 2).9 In 
general, the low potency associated with this compound 
class can be rationalized through consideration of the 
available X-ray crystal structure of compound 312 (Figure 
1). 
 
Figure 1. X-ray crystal structure of 3 in the Ligand Binding 
Domain of the GluA2 receptor with key interactions shown. 
The binding site is formed through association of two 
distinct lobes (S1 and S2) held together by a peptide to 
give a C2-symmetrical construct used for X-ray crystal-
lography.5 Examination of the biostructural data indicates 
that 3 makes no discernable interactions with the recep-
Leu 239 
 tor itself, and instead forms a single hydrogen bond with 
a network of water molecules. This limited interaction 
goes some way towards accounting for the modest po-
tency (37 PM) associated with the compound and is be-
lieved to be conserved in the series. Based on all of the 
above, we reasoned that using compound 3 as a starting 
point, it would be possible to evolve a new lead series by 
designing more optimal interactions with the receptor 
through hybridization with an unrelated class of modula-
tor. 
We recently reported a class of thiophene-amide de-
rived compounds (4 and 5),13,14 which more fully occupy 
the receptor binding site, establishing additional interac-
tions with the allosteric domain (Figure 2). The X-ray 
crystal structure of these compounds shows hydrophobic 
interactions of the pyrazole and benzothiophene rings 
with Pro and Leu residues, respectively. In addition, a 
hydrogen bonding interaction can be observed between 
the primary amide and a proximal Ser residue. This re-
sults in this class of compound having significantly im-
proved potency with EC50 values in the low micromolar 
range (e.g., EC50 for 5 = 0.40 PM), as well as profound 
effects on desensitization and deactivation (vide infra). In 
a related study,15 we have also demonstrated how the 
pyrazole motif could be used in a hybridization ap-
proach, combining features of unrelated classes of 
AMPA receptor modulators to furnish a new class of lig-
and. 
 
 
Figure 2. X-ray structure of compounds 4 (green) and 5 
(blue) in the GluA2 LBD. Both compounds span the entire 
allosteric site, making interactions with distal hydrophobic 
pockets. 
In this publication, we illustrate how this approach can 
be extended to generate a novel series of AMPA recep-
tor modulators though combination of the benzamide 
and thiophene amide derived systems. From considera-
tion of the binding modes of both the benzamide series 
and the more recent thiophene-derived systems, we 
concluded that hybridizing elements of both series could 
lead to a novel chemotype with enhanced potency com-
pared to the progenitor benzamide series. The basic 
design hypothesis is outlined in Chart 2.  
The pyrazole fragment from amide 5 was chosen for 
inclusion in the new template based on its highly con-
served binding mode as determined through previous 
biostructural work,13,15 thus providing confidence of how 
it is likely to interact with the receptor as part of a hybrid-
ized series. 
From consideration of the benzamide portion, we 
elected to base our hybrid compound on the tricyclic 
benzamide-derived scaffold represented by 6 (Chart 2). 
This progenitor compound which is formally related to 
both 2 and 3 has previously been reported as a modula-
tor of the AMPA receptor,15 and was selected as the ba-
sis of this approach as it offered greater synthetic tracta-
bility. 
 
Chart 2. Hybridization strategy adopted combining 
known classes of modulators, 5 and 6. 
Docking of the proposed hybrid compound 7 using the 
GOLD algorithm17 into the GluA2 LBD gave a favorable 
pose (Figure 3), with similar hydrophobic interactions 
with the allosteric domain being observed as for progeni-
tor compounds, 4 and 5. An additional hydrophobic in-
teraction was observed with the trifluoromethyl group, 
providing confidence that synthesis of related analogues 
would furnish new templates capable of interacting with 
the receptor.  
 
 
Figure 3. Docked pose of proposed benzamide hybrid 
compound 7 in the GluA2 LBD. 
Given the high level of structural information available 
at the outset of our synthesis campaign, we envisaged a 
focused chemistry effort, targeting specific compounds in 
order to ascertain the feasibility of our hybridization ap-
proach. Accordingly, in addition to compound 7 we se-
lected the analogs shown in Chart 3 for preparation. 
 
Pro 105 
Ser 242 
Ile 347 
Lys 359 
Pro 105 
Ser 242 
Ser 108 
Leu 239 
  
Chart 3. Additional hybrid compounds targeted for synthe-
sis. 
Based on the modeling data shown in Figure 3, a 
methylene linker unit was considered to be essential in 
order to achieve optimal interaction with the allosteric 
site. 
 
 
Scheme 1.a Preparation of Target Compounds  
aReagents and conditions: (a) (1) AcCl, MeOH, 0°C (2) 100 °C, 87% (b) 10 mol% BEMP, MeCN, 25 qC, 92%; (c) NaH, 
DMF, 120 qC, 70%; (d) trans-bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II), [HP(tBu)3]BF4, DBU, Mo(CO)6, 
MeCN/MeOH, 120 qC (PW), 62%; (e) LiAlH4, THF, 25 qC, 54%; (f) (1) SOCl2, CH2Cl2, 25 qC (2) (3-(trifluoromethyl)-1H-pyrazol-
4-yl)methanol, K2CO3, DMF, 60 qC, 26% (over 2 steps); (g) (1) 3-(trifluoromethyl)-1H-pyrazole-4-carbaldehyde, CuI, trans-1,2-
diaminocyclohexane, K2CO3, 1,4-dioxane, 180 qC (PW) (2) NaBH4, MeOH, 25 qC, 11% (over 2 steps); (h) Et3N, CH2Cl2, 25 qC, 
98%; (i) as (c), 72%; (j) trans-bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II), [HP(tBu)3]BF4, DBU, Mo(CO)6, 
MeCN/MeOH, 110 qC, 87%; (k) as (e), 70%; (l) as (f), 22% (over 2 steps) 
The site FRQWDLQVDµVDGGOH¶UHJLRQLQWKHFHQWHURIWKH
C2-symmetrical domain, therefore a flexible linker was 
included in the design of compound 7. The correspond-
ing fused analogue 8 was targeted as a control, with this 
more rigid structure not anticipated to be accommodated 
in the allosteric site. The sulfonamide hybrid 9 was se-
lected in order to probe spatial requirements in the re-
gion of the hydrophobic pocket. Additionally, previous 
work on benzamide related derivatives had indicated 
that sulfonamide derivatives could be tolerated in this 
region of the molecule,18 as well as other sulfonamide 
derived compounds which target hydrogen bond interac-
tions with Pro105.19,20 
Target compounds 7 ± 9 were prepared as shown in 
Scheme 1. Base-mediated amidation of the benzoate 
ester 1121 followed by SNAr cyclization furnished tricylic 
intermediate 14. This could be converted to target com-
pound 8 in two steps (copper-mediated arylation and 
subsequent reduction). Alternatively, 14 could be sub-
MHFWHG WR D FDUERQ\ODWLRQ SURFHGXUH ZLWK +HUUPDQQ¶V
catalyst,22 followed by a sequence of reduction, 
cholorination and alkylation to furnish the requisite pyra-
zole derivative 7. The corresponding sulfonamide system 
9 was accessed in an analogous fashion, starting from 
the aryl sulfonyl chloride building block 18. 
Each of the analogs were then examined in an electro-
physiological assay in order to assess their efficacy as 
positive allosteric modulators of the AMPA receptor. In 
this study, two separate splice variants of the GluA2 re-
ceptor, termed flip and flop were employed. These varia-
tions can lead to differences in the kinetic and pharma-
cological properties of the channel and particularly mani-
fest in the allosteric site where an N754S mutation oc-
curs.7 Based on this, we sought to explore the pharma-
cology of our nascent compounds against both splice 
variants. 
 AMPA receptor potentiation by an exogenous ligand is 
a product of its impact on two processes: deactivation 
and desensitization. Deactivation involves the channel 
being at rest following dissociation of the endogenous 
ligand (glutamate), whereas desensitization involves the 
closure of the channel with glutamate still bound. For the 
AMPA receptors, these processes occur on a very rapid 
timescale (1-2 milliseconds and 10 milliseconds, respec-
tively) and are pivotal in shaping the duration and ampli-
tude of response to glutamate at a synapse. Inhibition of 
either or both of these responses will lead to potentiation 
of the receptor. Accordingly, we sought to determine the 
effects of our novel compounds against both desensiti-
zation and deactivation. Compounds were tested at a 
single concentration of 30 PM, with the highly potent 
analog 5 (which was previously shown to be effective 
against both processes and tested here at a concentra-
tion of 100 PM14) used for comparison. Earlier efforts 
from our laboratories23 have shown how comparing elec-
trophysiological profiles within a series can be used to 
determine relative efficacy and affinity of individual ex-
emplars using a single test concentration.  
GluA2 flip or flop receptor cDNA was transiently-
transfected and expressed in HEK 293 cells. Outside-out 
membrane patches containing homomeric GluA2 were 
pulled and positioned within the control stream of a two-
barrel flowpipe. This stream was then rapidly switched to 
the adjacent compound-containing stream for 1 millisec-
ond or 500 milliseconds to record receptor deactivation 
or desensitization, respectively. 
As demonstrated previously,14 compound 5 was effec-
tive at modulating deactivation of both flip (p<0.05) and 
flop (p<0.05) GluA2 homomers (Figure 4A), one of a lim-
ited number of compounds which demonstrates a modu-
latory effect on flip deactivation. Similarly, though not 
affecting desensitization kinetics (Figure 4B, flip: p=0.82, 
flop: p=0.85), compound 5 increased the steady-state 
current observed with receptor desensitization on both 
isoforms (Figure 4C, flip, flop: p<0.001). Based on our 
recent analysis of decay current produced by the onset 
of densistization,23 behavior of this type is indicative of a 
compound with low affinity and low efficacy.  
By comparison, compound 7 was significantly more ef-
fective than 5 at modulating deactivation of flop isoforms 
(p<0.001), even at the lower concentrations tested, but 
no longer showed an effect on flip GluA2 (p=0.64, Fig 
4A). This flop isoform specific effect of 7 was also ob-
served for desensitization kinetics, displaying a slowed 
onset of desensitization for flop receptors (p<0.001) not 
observed on flip isoforms (p=0.77) or with compound 5 
(Fig 4B).  Despite this isoform specificity relating to onset 
of desensitization, compound 7 showed an enhanced 
steady-state current on both flip (p<0.001) and flop 
(p<0.001) receptors (Fig 4C).  Our previous study23 sug-
gests that slowing of desensitization together with robust 
block of steady-state current is indicative of a compound 
with high efficacy and high affinity. In this regard, com-
pound 7 represents a significant advance on compound 
5 (vide supra). 
 
These apparently detached patterns of receptor kinet-
ics were further observed with the hybridized compound 
9.  This compound showed no observable effect on de-
activation kinetics (flip: p=0.64, flop: p=0.46, Fig 4A) or 
steady-state current (flip: p=0.24, flop: p=0.25 Fig 4C), 
but demonstrated a most pronounced effect on desensi-
tization kinetics specific to the flop isoform (p<0.001, Fig 
4B), with a slight effect on flip receptors (p=0.05).  Final-
ly, there was no observed modulation by compound 8 on 
either isoform for any tested measure (deactivation: flip: 
p=0.12, flop: p=0.96; desensitization: flip: p=0.54, flop: 
p=0.87; SS/Peak: flip: p=0.20, flop: p=0.55). 
The electrophysiological data presented above indi-
cates that for meaningful activity at the GluA2 receptor 
an appropriate spacer must be incorporated into the hy-
bridized compounds (c.f. compounds 7 and 8). This ob-
servation is consistent with our earlier design hypothesis 
informed through consideration of the X-ray structure of 
the allosteric site. The new hybrid compound 7 is able to 
robustly block the process of desensitization against 
both flip and flop receptor isoforms, showing encourag-
ing levels of efficacy as an AMPA receptor modulator 
and compares favorably with progenitor compounds 
such as 2, 3 and 5.  
 
 
Figure 4. Electrophysiology data for tested compounds in 
both flip and flop receptors showing: A deactivation; B de-
sensitization; and C steady-state/peak ratios. 
 The subtype preference observed with compound 7 for 
slowing of on-set of desensitization and deactivation is 
not readily explained through use of the available 
biostructural data and attempts to generate biostructural 
data have so far not proven to be fruitful. It can be re-
marked, however, that this subtype preference has been 
observed for progenitor compounds (e.g. 3), and so is 
likely to be a function of the benzamide chemotype.10  
Lastly, the sulfonamide analogue 9, despite slowing 
on-set of desensitization does not exhibit any measura-
ble degree of efficacy as a desensitization blocker as 
evidenced by its negligible effect on the steady-state to 
peak ratio. This indicates a strong preference for the 
benzamide moiety as a preferred chemotype. 
In summary, hybridization of two distinct lead series 
with contrasting levels of affinity and efficacy has fur-
nished a new chemotype with a high amplitude of modu-
lation of the AMPA receptor. This new chemotype repre-
sented by compound 7 compares very favourably with 
highly potent modulators (e.g. 5) identified previously in 
terms of tonic potency, affinity and efficacy. The use of 
biostructural information has greatly enabled the design 
process and led to the expedient generation of new tools 
with which to further interrogate the biology of the AMPA 
receptor. 
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